SL
MRNA icon

Savior LLC’s Moderna MRNA Stock Holding History

Savior LLC’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-171
Closed -$5K – 844
2020
Q1 		$5K Buy
+171
New +$3.93K 0.01% 447

Other funds holding MRNA

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Savior LLC's MRNA Position: Q2 2020 in Review

Savior LLC sold out of Moderna (MRNA) in Q2 2020, closing a stake of 171 shares — an estimated $5K sold.

Savior LLC first reported a position in MRNA in Q1 2020 and held it in 1 quarter. The position peaked at $5K in Q1 2020. 489 funds tracked by Wall St. Rank hold MRNA as of Q2 2020.

  • Savior LLC reported no remaining Moderna position as of Q2 2020 after selling out during the quarter.
  • Savior LLC sold 171 Moderna shares in Q2 2020, an estimated $5K.
  • Savior LLC first reported a position in Moderna in Q1 2020 and held it in 1 quarter.
  • Savior LLC's Moderna position peaked at $5K in Q1 2020.
  • 489 funds tracked by Wall St. Rank held Moderna as of Q2 2020.

Based on Savior LLC's 13F filing for Q2 2020, filed 28 Jul 2020.